296 related articles for article (PubMed ID: 33254278)
1. Prognosis of medication-related osteonecrosis of the jaws in metastatic prostate cancer patients.
Wei LY; Kok SH; Lee YC; Chiu WY; Wang JJ; Cheng SJ; Chang HH; Lee JJ
Oral Dis; 2022 Jan; 28(1):182-192. PubMed ID: 33254278
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.
Wei LY; Kok SH; Lee YC; Chiu WY; Wang JJ; Cheng SJ; Chang HH; Lee JJ
J Formos Med Assoc; 2021 Aug; 120(8):1572-1580. PubMed ID: 33309430
[TBL] [Abstract][Full Text] [Related]
3. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
[TBL] [Abstract][Full Text] [Related]
4. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
Support Care Cancer; 2022 Mar; 30(3):2341-2348. PubMed ID: 34738163
[TBL] [Abstract][Full Text] [Related]
5. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
[TBL] [Abstract][Full Text] [Related]
7. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
[TBL] [Abstract][Full Text] [Related]
8. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
9. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
[TBL] [Abstract][Full Text] [Related]
10. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
[TBL] [Abstract][Full Text] [Related]
11. Medication-Related Osteonecrosis of the Jaws in the Pediatric Population.
Neal TW; Schlieve T
J Oral Maxillofac Surg; 2022 Oct; 80(10):1686-1690. PubMed ID: 35931181
[TBL] [Abstract][Full Text] [Related]
12. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis.
Limones A; Sáez-Alcaide LM; Díaz-Parreño SA; Helm A; Bornstein MM; Molinero-Mourelle P
Med Oral Patol Oral Cir Bucal; 2020 May; 25(3):e326-e336. PubMed ID: 32271321
[TBL] [Abstract][Full Text] [Related]
13. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
14. Influence of prostate cancer status on the prevalence of medication-related osteonecrosis of the jaw.
Yasui T; Kimura M; Nagamine H; Yajima S; Karube T; Sato H; Asoda S; Hara S; Onizawa K
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Mar; 131(3):312-318. PubMed ID: 33431343
[TBL] [Abstract][Full Text] [Related]
15. Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study.
Hallmer F; Bjarnadottir O; Götrick B; Malmström P; Andersson G
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Sep; 130(3):252-257. PubMed ID: 32536575
[TBL] [Abstract][Full Text] [Related]
16. Is serum C-terminal telopeptide cross-link of type 1 collagen a reliable parameter for predicting the risk of medication-related osteonecrosis of the jaws? A systematic review and meta-analysis of diagnostic test accuracy.
Traboulsi-Garet B; Jorba-García A; Camps-Font O; Alves FA; Figueiredo R; Valmaseda-Castellón E
Clin Oral Investig; 2022 Mar; 26(3):2371-2382. PubMed ID: 35124731
[TBL] [Abstract][Full Text] [Related]
17. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
Fusco V; Campisi G; Bedogni A
Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
[TBL] [Abstract][Full Text] [Related]
18. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
20. Medication-Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium.
Yang G; Williams R; Wang L; Farhadfar N; Chen Y; Loiacono AT; Bian J; Holliday LS; Katz J; Gong Y
J Bone Miner Res; 2022 Dec; 37(12):2466-2471. PubMed ID: 36151778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]